NexImmune priced shares at $17 to raise $110m in an upsized offering, enabling Amgen and Pfizer to exit the Johns Hopkins University spinout.

The hearing loss treatment developer has raised more than $127m in its initial public offering that offered exits to Alphabet, GlaxoSmithKline and Regeneron.

NexImmune priced shares at $17 to raise $110m in an upsized offering, enabling Amgen and Pfizer to exit the Johns Hopkins University spinout.

Takeda Ventures and Alexandria Venture Investments have taken part in a $70m series A round for Ensoma, with Takeda separately signing a strategic collaboration deal.

Dexcel Pharma has co-led a $60m series A round for Immunai, which previously collected $20m in seed financing less than a year ago.

Eli Lilly has led a series C round for the diabetes treatment developer, which plans to complete preclinical testing of its lead therapy.

San Francisco Employees’ Retirement System commits $48m.

Illumina has also gathered £20m ($25m) to every graduate from its UK-based accelerator.

Ensemble Innovation Ventures Fund (EIVF) will target the health and wellness space.

Dexcom Ventures will invest in glucose sensing technology and adjacent areas.